The proposal combines IDRI’s vaccine-adjuvant technology and a micro-needle delivery device to create a device-adjuvant platform.
The platform will have the potential for intra-dermal delivery of a variety of vaccine products to combat some of world’s most challenging diseases for which vaccines are not currently available.
IDRI has been working on adjuvants – compounds used to improve the body’s immune response to vaccines – as a key research area for its malaria, tuberculosis, leishmaniasis, and leprosy vaccine development programs.
IDRI’s director of Formulations and Principal Investigator Darrick Carter said the grant will support IDRI’s proof-of-concept preclinical and Phase 1 clinical work to make a vaccine capable of being effective after a single shot.